NSCLC for phase 2 dose expansion

Clinical trials for NSCLC for phase 2 dose expansion explained in plain language.

Never miss a new study

Get alerted when new NSCLC for phase 2 dose expansion trials appear

Sign up with your email to follow new studies for NSCLC for phase 2 dose expansion, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Triple immunotherapy cocktail shows promise against tough cancers

Disease control Completed

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

Matched conditions: NSCLC FOR PHASE 2 DOSE EXPANSION

Phase 1/2 • Sponsor: BeiGene • Aim: Disease control

Last updated Jun 27, 2026 12:03 UTC

NSCLC for phase 2 dose expansion

Get alerted when new NSCLC for phase 2 dose expansion trials appear

Triple immunotherapy cocktail shows promise against tough cancers